Expert Interview
A second review of the recent FDA approval of AstraZeneca's Airsupra (albuterol/budesonide) the first and only rescue medication to reduce risk of asthma exacerbations in adults.
Ticker(s): AZNDr. Gondi is Board Certified in Allergy, Clinical Immunology, and Pediatrics. He Sees over 300 patients with Urticaria. He has Keen interest in treating allergic rhinitis, asthma, sinus disease, and insect sting allergies.He is a Diplomate of the American Board of Allergy and Immunology, Diplomate of the American Board of Pediatrics, and Fellow of the American Academy of Allergy, Asthma, and Immunology.
On a scale from 1 - 10 how would you rate your excitement regarding the FDA approval of airsupra?
Added By: ben_adminHow does airsupra compare and contrast to other available medications?
Added By: ben_adminHow does the approval of arisupra change the current treatment landscape?
Added By: ben_adminDo you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
